Catalio Capital Management, LP holds a focused book of 41 stocks worth $478.7M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Bridgebio Pharma Inc and trimmed Dianthus Therapeutics Inc. Their largest long position is Dianthus Therapeutics Inc at 10% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1958125/holdings"
Use Arkolith to show Catalio Capital Management, LP's latest holdings, largest changes, and filing provenance.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
85% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Dianthus Therapeutics Inc COM | $47.0M | 560.3K | 9.8% | ▼−14% Reduced · −93K sh | |
| 2 | Bridgebio Pharma Inc COM | $32.1M | 432.0K | 6.7% | ▲New New position | |
| 3 | Ascendis Pharma A/s SPONSORED ADR | $29.5M | 129.1K | 6.2% | ▲+8.3% Added · +10K sh | |
| 4 | Bristol-Myers Squibb Co COM | $25.5M | 420.7K | 5.3% | ▼−35% Reduced · −227K sh | |
| 5 | Syndax Pharmaceuticals Inc COM | $24.4M | 1.04M | 5.1% | ▼−13% Reduced · −153K sh | |
| 6 | Gilead Sciences Inc COM | $22.8M | 163.9K | 4.8% | ▼−43% Reduced · −125K sh | |
| 7 | Terns Pharmaceuticals Inc COM | $21.6M | 409.0K | 4.5% | ▲+199% Added · +272K sh | |
| 8 | Definium Therapeutics Inc COM SHS | $19.6M | 1.04M | 4.1% | ▲New New position | |
| 9 | Soleno Therapeutics Inc COM | $19.3M | 577.8K | 4.0% | ▲+60% Added · +217K sh | |
| 10 | Boston Scientific Corp COM | $18.8M | 299.3K | 3.9% | ▼−17% Reduced · −61K sh | |
| 11 | Ultragenyx Pharmaceutical In COM | $17.8M | 850.8K | 3.7% | ▲+423% Added · +688K sh | |
| 12 | Incyte Corp COM | $17.1M | 182.1K | 3.6% | ▲New New position | |
| 13 | Cytokinetics Inc COM NEW | $14.2M | 215.5K | 3.0% | ▼−17% Reduced · −43K sh | |
| 14 | Natera Inc COM | $14.2M | 70.9K | 3.0% | ▲+14% Added · +9K sh | |
| 15 | Corvus Pharmaceuticals Inc COM | $13.0M | 891.9K | 2.7% | ▲New New position | |
| 16 | Structure Therapeutics Inc SPONSORED ADS | $12.3M | 255.4K | 2.6% | ▲+1.0% Added · +2K sh | |
| 17 | Mineralys Therapeutics Inc COM | $11.9M | 439.0K | 2.5% | ▲+32% Added · +107K sh | |
| 18 | Edwards Lifesciences Corp COM | $11.6M | 144.6K | 2.4% | ▼−23% Reduced · −42K sh | |
| 19 | Veradermics Inc COMMON STOCK | $11.0M | 173.6K | 2.3% | ▲New New position | |
| 20 | Adaptive Biotechnologies Cor COM | $10.0M | 722.8K | 2.1% | ▼−12% Reduced · −98K sh | |
| 21 | Heartflow Inc COM | $9.8M | 403.6K | 2.1% | ▲+254% Added · +290K sh | |
| 22 | Kalvista Pharmaceuticals Inc COM | $8.6M | 426.6K | 1.8% | ▲New New position | |
| 23 | Uniqure NV SHS | $8.0M | 491.1K | 1.7% | ▲+70% Added · +203K sh | |
| 24 | Disc Medicine Inc COM | $7.9M | 123.0K | 1.6% | ▲+11% Added · +13K sh | |
| 25 | Septerna Inc COM | $7.1M | 294.4K | 1.5% | —Held | |
| 26 | Abivax Sa SPONSORED ADS | $5.3M | 47.2K | 1.1% | ▼−52% Reduced · −51K sh | |
| 27 | Dyne Therapeutics Inc COM | $5.1M | 283.0K | 1.1% | ▼−46% Reduced · −237K sh | |
| 28 | Eledon Pharmaceuticals Inc COM | $5.1M | 1.64M | 1.1% | ▲+30% Added · +380K sh | |
| 29 | Karyopharm Therapeutics Inc COM NEW | $5.0M | 897.7K | 1.0% | ▲+528% Added · +755K sh | |
| 30 | Supernus Pharmaceuticals COM | $3.2M | 62.0K | 0.7% | ▼−76% Reduced · −195K sh | |
| 31 | Protara Therapeutics Inc COM STK | $3.0M | 580.0K | 0.6% | ▼−60% Reduced · −866K sh | |
| 32 | Phathom Pharmaceuticals Inc COM | $2.8M | 247.8K | 0.6% | ▼−65% Reduced · −451K sh | |
| 33 | Newamsterdam Pharma Company ORDINARY SHARES | $2.7M | 83.6K | 0.6% | ▲New New position | |
| 34 | Tyra Biosciences Inc COM | $2.6M | 67.3K | 0.5% | ▲New New position | |
| 35 | Immunocore Hldgs PLC ADS | $2.5M | 84.4K | 0.5% | ▲New New position | |
| 36 | Fractyl Health Inc COM | $2.5M | 5.49M | 0.5% | —Held | |
| 37 | Hyperfine Inc COM CL A | $1.4M | 1.32M | 0.3% | —Held | |
| 38 | Metagenomi Therapeutics Inc COM | $709K | 529.0K | 0.1% | —Held | |
| 39 | Ataibeckley Inc COM SHS | $697K | 196.9K | 0.1% | ▲New New position | |
| 40 | Sensei Biotherapeutics Inc COM NEW | $464K | 14.7K | 0.1% | —Held | |
| 41 | Outset Med Inc COM NEW | $454K | 118.3K | 0.1% | —Held |
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.